Metronomic Chemotherapy of Capecitabine After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer
NCT02012634 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 340
Last updated 2014-11-13
Summary
A Multi-center, III Phase,Randomized Controlled Clinical Study of Capecitabine Metronomic Chemotherapy After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer
Conditions
- Breast Cancer
- Capecitabine
- Triple Negative Breast Cancer
Sponsors & Collaborators
-
Roche Pharma AG
collaborator INDUSTRY -
Xijing Hospital
lead OTHER
Principal Investigators
-
Nanlin Li, Doctor · Air Force Military Medical University, China
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-01-31
- Primary Completion
- 2015-12-31
- Completion
- 2018-12-31
Countries
- China
Study Locations
More Related Trials
-
Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer
NCT05089643 ·Status: UNKNOWN ·Phase: PHASE2
-
Capecitabine Metronomic Chemotherapy Plus Aromatase Inhibitor for Postmenopausal Hormone Receptor Positive Breast Cancer
NCT01924078 ·Status: UNKNOWN ·Phase: PHASE2
-
Capecitabine in the Treatment of Breast Cancer With Low-hormone Receptor Expression After Neoadjuvant Chemotherapy
NCT03821454 ·Status: UNKNOWN ·Phase: NA
-
Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer
NCT03775928 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients
NCT03561740 ·Status: RECRUITING ·Phase: PHASE3
-
Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer
NCT01928680 ·Status: UNKNOWN ·Phase: PHASE2
-
Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer
NCT07019337 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer
NCT04159142 ·Status: RECRUITING ·Phase: PHASE2
-
Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer
NCT02767661 ·Status: COMPLETED ·Phase: PHASE3
-
Sequential Neo-adjuvant Chemotherapy Followed by Capecitabine Vs. Conventional Adjuvant Chemotherapy in Breast Cancer
NCT03011060 ·Status: UNKNOWN ·Phase: PHASE3
-
the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line Treatment
NCT03358004 ·Status: TERMINATED ·Phase: PHASE2
-
Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC)
NCT01126138 ·Status: UNKNOWN ·Phase: PHASE3
-
Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer
NCT05063136 ·Status: RECRUITING ·Phase: PHASE3
-
An All-Oral Combination of Capecitabine and Cyclophosphamide in Patients With Metastatic Breast Cancer (MBC)
NCT00589901 ·Status: UNKNOWN ·Phase: PHASE2
-
Pyrotinib Combined With Capecitabine in HER-2 Positive Advanced Breast Cancer and Brain Metastases (Post-PERMEATE)
NCT05359120 ·Status: UNKNOWN
-
Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC
NCT01917279 ·Status: UNKNOWN ·Phase: PHASE3
-
Mitoxantrone Hydrochloride Liposome Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast Cancer
NCT06156761 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer
NCT05172518 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer
NCT06685796 ·Status: RECRUITING ·Phase: PHASE2
-
Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer
NCT03204734 ·Status: UNKNOWN ·Phase: PHASE2
-
Low Dose of Metronomic Cyclophosphamide and Capecitabine in Pretreated HER2-negative Metastatic Breast Cancer
NCT01526512 ·Status: UNKNOWN ·Phase: PHASE2
-
Capecitabine as Maintenance Therapy vs Observation in Early-stage Triple-negative Breast Cancer
NCT07143097 ·Status: COMPLETED ·Phase: PHASE2
-
Metronomic Chemotherapy in a Real-world Population of Advanced Breast Cancer Patients
NCT06373744 ·Status: COMPLETED
-
Oral Vinorelbine and Capecitabine in Advanced HER2-negative Breast Cancer
NCT05747326 ·Status: UNKNOWN ·Phase: PHASE2
-
A Multicenter, Randomized Clinical Trail Evaluate Effectiveness and Security of Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen After the 1st-line Chemotherapy With Capecitabine Combine Regimen in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer(Overstep)
NCT02597868 ·Status: UNKNOWN ·Phase: NA